1h Free Analyst Time
The publisher has been monitoring the cancer monoclonal antibodies market and it is poised to grow by $33.1 bn during 2021-2025, progressing at a CAGR of 8.23% during the forecast period. Our report on cancer monoclonal antibodies market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.Speak directly to the analyst to clarify any post sales queries you may have.
The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by the increase in demand for ADCs and awareness and initiatives taken by vendors and government.
The cancer monoclonal antibodies market analysis includes the type segment and geographic landscape.
The cancer monoclonal antibodies market is segmented as below:
By Type
- Naked monoclonal antibodies
- Conjugated and bi-specific monoclonal antibodies
By Geographical Landscape
- North America
- Europe
- Asia
- ROW
This study identifies the strong R&D pipeline as one of the prime reasons driving the cancer monoclonal antibodies market growth during the next few years.
The report on cancer monoclonal antibodies market covers the following areas:
- Cancer monoclonal antibodies market sizing
- Cancer monoclonal antibodies market forecast
- Cancer monoclonal antibodies market industry analysis
The publisher's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading cancer monoclonal antibodies market vendors that include Amgen Inc., Astellas Pharma Inc., AstraZeneca Plc, Bristol Myers Squibb Co., F. Hoffmann La Roche Ltd., Johnson and Johnson Inc., Merck and Co. Inc., Novartis AG, Pfizer Inc., and Sanofi SA. Also, the cancer monoclonal antibodies market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.
Table of Contents
Executive Summary- Market overview
Market Landscape
- Market ecosystem
- Value chain analysis
Market Sizing
- Market definition
- Market segment analysis
- Market size 2020
- Market outlook: Forecast for 2020 - 2025
Five Forces Analysis
- Bargaining power of buyers
- Bargaining power of suppliers
- Threat of new entrants
- Threat of substitutes
- Threat of rivalry
- Market condition
Market Segmentation by Type
- Market segments
- Comparison by Type
- Naked monoclonal antibodies - Market size and forecast 2020-2025
- Conjugated and bi-specific monoclonal antibodies - Market size and forecast 2020-2025
- Market opportunity by Type
Customer landscape
Geographic Landscape
- Geographic segmentation
- Geographic comparison
- North America - Market size and forecast 2020-2025
- Europe - Market size and forecast 2020-2025
- Asia - Market size and forecast 2020-2025
- ROW - Market size and forecast 2020-2025
- Key leading countries
- Market opportunity By Geographical Landscape
- Market drivers
- Market challenges
- Market trends
Vendor Landscape
- Landscape disruption
Vendor Analysis
- Vendors covered
- Market positioning of vendors
- Amgen Inc.
- Astellas Pharma Inc.
- AstraZeneca Plc
- Bristol Myers Squibb Co.
- F. Hoffmann La Roche Ltd.
- Johnson and Johnson Inc.
- Merck and Co. Inc.
- Novartis AG
- Pfizer Inc.
- Sanofi SA
Appendix
- Scope of the report
- Currency conversion rates for US$
- Research methodology
- List of abbreviations
List of Exhibits
- Key Finding 1
- Key Finding 2
- Key Finding 3
- Key Finding 5
- Key Finding 6
- Key Finding 7
- Key Finding 8
- Parent market
- Market characteristics
- Offerings of vendors included in the market definition
- Market segments
- Global - Market size and forecast 2020 - 2025 ($ million)
- Global market: Year-over-year growth 2020 - 2025 (%)
- Five forces analysis 2020 & 2025
- Bargaining power of buyers
- Bargaining power of suppliers
- Threat of new entrants
- Threat of substitutes
- Threat of rivalry
- Market condition - Five forces 2020
- Type - Market share 2020-2025 (%)
- Comparison by Type
- Naked monoclonal antibodies - Market size and forecast 2020-2025 ($ million)
- Naked monoclonal antibodies - Year-over-year growth 2020-2025 (%)
- Conjugated and bi-specific monoclonal antibodies - Market size and forecast 2020-2025 ($ million)
- Conjugated and bi-specific monoclonal antibodies - Year-over-year growth 2020-2025 (%)
- Market opportunity by Type
- Customer landscape
- Market share By Geographical Landscape 2020-2025 (%)
- Geographic comparison
- North America - Market size and forecast 2020-2025 ($ million)
- North America - Year-over-year growth 2020-2025 (%)
- Europe - Market size and forecast 2020-2025 ($ million)
- Europe - Year-over-year growth 2020-2025 (%)
- Asia - Market size and forecast 2020-2025 ($ million)
- Asia - Year-over-year growth 2020-2025 (%)
- ROW - Market size and forecast 2020-2025 ($ million)
- ROW - Year-over-year growth 2020-2025 (%)
- Key leading countries
- Market opportunity By Geographical Landscape ($ million)
- Impact of drivers and challenges
- Vendor landscape
- Landscape disruption
- Industry risks
- Vendors covered
- Market positioning of vendors
- Amgen Inc. - Overview
- Amgen Inc. - Business segments
- Amgen Inc. - Key offerings
- Amgen Inc. - Key customers
- Amgen Inc. - Segment focus
- Astellas Pharma Inc. - Overview
- Astellas Pharma Inc. - Product and service
- Astellas Pharma Inc. - Key offerings
- Astellas Pharma Inc. - Key customers
- Astellas Pharma Inc. - Segment focus
- AstraZeneca Plc - Overview
- AstraZeneca Plc - Product and service
- AstraZeneca Plc - Key offerings
- AstraZeneca Plc - Key customers
- AstraZeneca Plc - Segment focus
- Bristol Myers Squibb Co. - Overview
- Bristol Myers Squibb Co. - Product and service
- Bristol Myers Squibb Co. - Key offerings
- Bristol Myers Squibb Co. - Key customers
- Bristol Myers Squibb Co. - Segment focus
- F. Hoffmann La Roche Ltd. - Overview
- F. Hoffmann La Roche Ltd. - Business segments
- F. Hoffmann La Roche Ltd. - Key offerings
- F. Hoffmann La Roche Ltd. - Key customers
- F. Hoffmann La Roche Ltd. - Segment focus
- Johnson and Johnson Inc. - Overview
- Johnson and Johnson Inc. - Business segments
- Johnson and Johnson Inc. - Key offerings
- Johnson and Johnson Inc. - Key customers
- Johnson and Johnson Inc. - Segment focus
- Merck and Co. Inc. - Overview
- Merck and Co. Inc. - Business segments
- Merck and Co. Inc. - Key offerings
- Merck and Co. Inc. - Key customers
- Merck and Co. Inc. - Segment focus
- Novartis AG - Overview
- Novartis AG - Business segments
- Novartis AG - Key offerings
- Novartis AG - Key customers
- Novartis AG - Segment focus
- Pfizer Inc. - Overview
- Pfizer Inc. - Business segments
- Pfizer Inc. - Key offerings
- Pfizer Inc. - Key customers
- Pfizer Inc. - Segment focus
- Sanofi SA - Overview
- Sanofi SA - Business segments
- Sanofi SA - Key offerings
- Sanofi SA - Key customers
- Sanofi SA - Segment focus
- Currency conversion rates for US$
- Research Methodology
- Validation techniques employed for market sizing
- Information sources
- List of abbreviations
Executive Summary
The publisher recognizes the following companies as the key players in the global cancer monoclonal antibodies market: Amgen Inc., Astellas Pharma Inc., AstraZeneca Plc, Bristol Myers Squibb Co., F. Hoffmann La Roche Ltd., Johnson and Johnson Inc., Merck and Co. Inc., Novartis AG, Pfizer Inc., and Sanofi SA.Commenting on the report, an analyst from the research team said: `The latest trend gaining momentum in the market is Strong R&D pipeline.`
According to the report, one of the major drivers for this market is the increase in demand for ADCs.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Amgen Inc.
- Astellas Pharma Inc.
- AstraZeneca Plc
- Bristol Myers Squibb Co.
- F. Hoffmann La Roche Ltd.
- Johnson and Johnson Inc.
- Merck and Co. Inc.
- Novartis AG
- Pfizer Inc.
- Sanofi SA
